Our
partners

CDR-Life is developing highly targeted T cell engagers (TCE) to eliminate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We leverage this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to fight tumors.

Founded in 2001, HBM Partners focuses on venture, growth and buy-out financings of private companies as well as on investments in public companies in the biopharma, medtech, diagnostics and healthcare sectors.

“Together with Life Science Cares we want to be involved in nurturing futures by supporting the community and empowering young people.”

CUSTOM-BUILT BIOLOGY FOR PATIENTS

We are pioneering DARPin therapeutics to go beyond the limits of today’s leading treatments

Numab is developing new medicines to treat inflammation and cancer. Their most promising medicine is being developed with the goal of providing a permanent cure for atopic dermatitis and possibly other diseases.

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases.

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members, the association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.

The Wyss Zurich Translational Center is an innovation accelerator affiliated with ETH Zurich and the University of Zurich. It supports projects in the fields of regenerative medicine, robotics, and medical devices/bionics, aiming to translate innovative therapies, technologies, and intelligent systems from research into clinical application.

Cellvie is developing Therapeutic Mitochondria Transplantation, a groundbreaking treatment focused on improving cellular energy metabolism. The initial application targets ischemia-reperfusion injuries, particularly in kidney transplants and heart attack patients, with the broader goal of creating a versatile platform.

Superlab Suisse, founded in Zurich in 2019, offers serviced laboratory spaces, consumable solutions, and a wide range of partnerships to support life science companies at all stages. They operate in Lausanne, Basel, and Zurich.

Nxera Pharma is a tech-driven biopharma company focused on specialty medicines for unmet needs in Japan and globally. With 30+ active programs in neurology, GI, immunology, metabolic, and rare diseases, Nxera employs 350+ people across Japan, the UK, Switzerland, and South Korea.

Adoram is dedicated to developing superior immunotherapies that are both safer and more potent through an allosteric mode of action.

Enables the next generation through early stage Biotech and Medtech investments.

Azafaros is a clinical-stage biotech targeting rare genetic lysosomal storage disorders with oral small molecules, including nizubaglustat.

The regional Caritas organizations are committed to helping people affected by poverty in Switzerland, regardless of nationality or ideology.

The regional Caritas organizations are committed to helping people affected by poverty in Switzerland, regardless of nationality or ideology.

The Swiss Red Cross regional chapters help people in every situation, of every age and regardless of their origin.

The Swiss Red Cross regional chapters help people in every situation, of every age and regardless of their origin.

The Swiss Food Bank Foundation collects around 30 tons of perfectly good surplus food every day from retailers, wholesalers and industry and distributes it free of charge to over 500 social institutions such as homeless shelters, soup kitchens, emergency shelters and women’s refuges.

The social institutions and businesses of the city of Zurich contribute to professional and social integration.